GE HealthCare to Showcase Emerging PET/CT Technologies at SNMMI Conference
In addition to new advances in PET/CT imaging to facilitate precision imaging, the company will also unveil a device at the SNMMI conference that allows in-house production of commercial PET tracers.
Emphasizing precision imaging, GE HealthCare will feature a variety of emerging positron emission tomography/computed tomography (PET/CT) modalities at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNNMI) conference.
One of the showcased modalities is the Omni Legend 21 cm, a PET/CT system that reportedly offers bolstered quality for oncologic imaging, improved capability with cardiac tracers and enhanced visualization of amyloid volume associated with Alzheimer’s disease, according to GE HealthCare.
GE HealthCare is showing the Omni Legend 21 cm PET/CT system at the 2024 SNMMI conference. Currently not cleared by the FDA nor licensed in Canada, the emerging technology reportedly offers bolstered quality for oncologic imaging and enhanced visualization of amyloid volume associated with Alzheimer’s disease, according to GE HealthCare. (Image courtesy of GE HealthCare.)
GE HealthCare said other technologies debuting at SNMMI include:
• the MINItrace Magni, a device that enables cost-effective, in-house production of commercial PET tracers;
• the portable PET/CT Omni Legend Mobile, which may facilitate improved access to nuclear medicine imaging at regional or local hospital facilities; and
• the bone SPECT trained Clarify DL, which offers improved noise reduction with deep learning reconstruction.
“While there is still much work to be done, we are proud to offer a variety of technologies that can evolve with healthcare system needs and help support a patient’s entire care journey – from the systems required to create the radiotracers used to diagnose and monitor disease, to the imaging equipment used for a noninvasive look at a patient’s anatomy and treatment monitoring, to the software optimized to measure lesion size and dose,” noted Jean-Luc Procaccini, the president and chief executive officer of molecular imaging and computed tomography at GE HealthCare. “In the hands of clinicians, these tools help make the practice of precision care more accessible and aim to help improve patient outcomes globally.”
GE HealthCare noted that Clarify DL is pending 510(k) clearance from the Food and Drug Administration (FDA) and is currently not licensed for use in Canada. The company said the Omni Legend 21 cm is currently not cleared by the FDA nor licensed in Canada. The MINItrace Magni is currently in ongoing development, according to GE HealthCare.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
New Analysis Forecasts Substantial Cost Savings with the Use of Photon Counting CT for CCTA
March 8th 2025The use of ultra-high-resolution photon-counting CT in the evaluation of stable chest pain may significantly reduce follow-up tests and invasive coronary angiography (ICA) procedures, possibly resulting in millions in health-care cost savings, according to a cost-effectiveness analysis presented recently at the European Congress of Radiology.
Can Deep Learning Ultra-Fast bpMRI Have an Impact in Prostate Cancer Imaging?
March 3rd 2025A deep learning-enhanced ultra-fast bpMRI protocol offered similar sensitivity for csPCa as mpMRI with an 80 percent reduction in scan time, according to research findings presented at the European Congress of Radiology (ECR) conference.
